A prospective open-label study of aripiprazole in fragile X syndrome.
about
Aripiprazole for treating irritability in children & adolescents with autism: A systematic reviewEmerging pharmacologic treatment options for fragile X syndromeAripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-AnalysisTranslational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trialFRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIESChanges in sensitivity of reward and motor behavior to dopaminergic, glutamatergic, and cholinergic drugs in a mouse model of fragile X syndromeDeveloping a utility index for the Aberrant Behavior Checklist (ABC-C) for fragile X syndrome.Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome.A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study.Prolactin serum concentrations during aripiprazole treatment in youth.Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Outcome measures for clinical trials in fragile X syndrome.The challenges of clinical trials in fragile X syndrome.Development of mavoglurant and its potential for the treatment of fragile X syndrome.Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.Molecular medicine of fragile X syndrome: based on known molecular mechanisms.Public Health Literature Review of Fragile X Syndrome.Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder.Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings
P2860
Q26784199-06777807-B0F5-4F00-8A37-E0E467B9E4EDQ26829152-EA56EE2A-B8B9-4645-B808-03EF980C804BQ28073540-7519ECF0-FDA4-4ED6-B8DE-16F13A59B1BBQ28394524-D37EACDC-ECCA-4F1F-99B9-E5AFC54DB7F2Q33785978-D1BE99EE-74E7-4416-877E-B0A17264634FQ34207747-C48BB3A3-5C56-4EA0-828F-9ADDA02C8FCCQ35013074-4AA7FE5C-5518-489A-906C-11866E16D6FAQ35035766-2CB03529-1E3D-49AD-B832-2CA5DE8C30DFQ35050550-302FD189-1671-4A7E-AA58-C16BC650EDD7Q35614072-7C8940ED-AD62-4F98-8839-A8BD92C96516Q36147870-A11DCB7D-651D-4421-8D9D-7AD93298C17EQ36157807-6DFE3F1A-6DD8-48DE-9836-33561C8E2FCFQ36853126-56C86E4C-5F95-469A-8064-7A4C6B302714Q37054398-1411D761-5B5F-434C-B7E3-3EDF90A185EAQ37199656-E52B3622-0A30-41FC-B5E3-15359F2D20BBQ37598441-2B25053F-F046-43E2-BD80-97D14B02829AQ38164021-448CE672-9560-4A6F-A127-0BA12775D1A1Q38621496-01C25B86-199A-4F44-89AA-EEA5FC5D5575Q38627691-706F6228-234A-467A-A02C-3EE33FA724F3Q38641503-6FA3E4DD-5A51-457A-BA08-3E447CD27F90Q47850608-0F1CB45C-AEA2-45B9-ABC7-5B838552BE85Q59292055-2D388CF8-F085-4C67-A21E-50BD630C83CD
P2860
A prospective open-label study of aripiprazole in fragile X syndrome.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A prospective open-label study of aripiprazole in fragile X syndrome.
@en
A prospective open-label study of aripiprazole in fragile X syndrome.
@nl
type
label
A prospective open-label study of aripiprazole in fragile X syndrome.
@en
A prospective open-label study of aripiprazole in fragile X syndrome.
@nl
prefLabel
A prospective open-label study of aripiprazole in fragile X syndrome.
@en
A prospective open-label study of aripiprazole in fragile X syndrome.
@nl
P2093
P2860
P1433
P1476
A prospective open-label study of aripiprazole in fragile X syndrome.
@en
P2093
Arlene Kohn
Craig A Erickson
David J Posey
Jennifer E Mullett
Kimberly A Stigler
Logan K Wink
P2860
P2888
P356
10.1007/S00213-011-2194-7
P577
2011-02-12T00:00:00Z